Perfuse Therapeutics

Perfuse Therapeutics is a private, clinical-stage biopharmaceutical company developing disease-modifying therapies for ischemia-mediated ocular diseases. The company is focused on improving retinal and optic nerve blood flow by blocking pathologic endothelin signaling, a mechanism it positions as a first-in-class approach in ophthalmology. Its lead program, PER-001, is a sustained-release intravitreal implant delivering a small-molecule endothelin antagonist and has generated Phase 1/2a and Phase 2 data in glaucoma and diabetic retinopathy. Perfuse is also positioning the same core approach for additional retinal ischemic diseases such as dry age-related macular degeneration and retinal vein occlusion. The company combines ocular therapeutics development with a proprietary local drug-delivery platform intended to provide approximately six months of drug release per administration.